DI
NKTR icon

Deeter Investments’s Nektar Therapeutics NKTR Stock Holding History

Deeter Investments’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-239,300
Closed -$17.2M – 129
2026
Q1 		$17.2M Buy
+239,300
New +$13.6M 1.93% 11

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Deeter Investments's NKTR Position: Q2 2026 in Review

Deeter Investments sold out of Nektar Therapeutics (NKTR) in Q2 2026, closing a stake of 239,300 shares — an estimated $17.2M sold.

Deeter Investments first reported a position in NKTR in Q1 2026 and held it in 1 quarter. The position peaked at $17.2M in Q1 2026. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Deeter Investments reported no remaining Nektar Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Deeter Investments sold 239,300 Nektar Therapeutics shares in Q2 2026, an estimated $17.2M.
  • Deeter Investments first reported a position in Nektar Therapeutics in Q1 2026 and held it in 1 quarter.
  • Deeter Investments's Nektar Therapeutics position peaked at $17.2M in Q1 2026.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Deeter Investments's 13F filing for Q2 2026, filed 8 Oct 2026.